المؤلفون: Roth EM; The Sterling Research Group, Cincinnati, OH, USA. Electronic address: eroth@sterlingresearch.org., Kastelein JJP; Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands., Cannon CP; Harvard Clinical Research Institute, Boston, MA, USA., Farnier M; Lipid Clinic, Point Médical and Department of Cardiology, CHU Dijon-Bourgogne, Dijon, France., McKenney JM; Virginia Commonwealth University, Richmond, VA, USA., DiCioccio AT; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Brunet A; Sanofi, Clinical Development, R&D, Montpellier, France., Manvelian G; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Sasiela WJ; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Baccara-Dinet MT; Sanofi, Clinical Development, R&D, Montpellier, France., Zhao J; Regeneron Pharmaceuticals Inc., Basking Ridge, NJ, USA., Robinson JG; University of Iowa, Iowa City, IA, USA.

المصدر: Journal of clinical lipidology [J Clin Lipidol] 2020 Sep - Oct; Vol. 14 (5), pp. 707-719. Date of Electronic Publication: 2020 Jul 25.

نوع المنشور: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 101300157 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1933-2874 (Print) Linking ISSN: 18764789 NLM ISO Abbreviation: J Clin Lipidol Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal, Humanized/*therapeutic use , Cholesterol, LDL/*metabolism , Hypercholesterolemia/*drug therapy , Proprotein Convertase 9/*metabolism, Female ; Humans ; Hypercholesterolemia/metabolism ; Hypercholesterolemia/pathology ; Male ; Middle Aged ; Prognosis

المؤلفون: Langslet G; Lipid Clinic, Oslo University Hospital, Aker Sykehus, Bygg 6, Trondheimsveien 235, Postboks 4959 Nydalen, 0424, Oslo, Norway. glangsle@ous-hf.no., Hovingh GK; Academic Medical Center, Amsterdam, The Netherlands.; Novo Nordisk AS, Copenhagen, Denmark., Guyton JR; Duke University Medical Center, Durham, NC, USA., Baccara-Dinet MT; Clinical Development, R&D, Sanofi, Montpellier, France., Letierce A; Biostatistics and Programming, Sanofi, Chilly-Mazarin, France., Manvelian G; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Farnier M; Lipid Clinic, Point Médical and Department of Cardiology, CHU Dijon-Bourgogne, Dijon, France.

المصدر: Cardiovascular drugs and therapy [Cardiovasc Drugs Ther] 2020 Aug; Vol. 34 (4), pp. 515-523.

نوع المنشور: Clinical Trial; Comparative Study; Journal Article; Multicenter Study

بيانات الدورية: Publisher: Kluwer Academic For The International Society For Cardiovascular Pharmacotherapy Country of Publication: United States NLM ID: 8712220 Publication Model: Print Cited Medium: Internet ISSN: 1573-7241 (Electronic) Linking ISSN: 09203206 NLM ISO Abbreviation: Cardiovasc Drugs Ther Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal, Humanized/*administration & dosage , Anticholesteremic Agents/*administration & dosage , Healthcare Disparities/*trends , Hyperlipoproteinemia Type II/*drug therapy , Practice Patterns, Physicians'/*trends , Serine Proteinase Inhibitors/*administration & dosage, Adult ; Aged ; Antibodies, Monoclonal, Humanized/adverse effects ; Anticholesteremic Agents/adverse effects ; Biomarkers/blood ; Cholesterol, LDL/blood ; Drug Dosage Calculations ; Drug Utilization/trends ; Female ; Genetic Predisposition to Disease ; Heterozygote ; Humans ; Hyperlipoproteinemia Type II/blood ; Hyperlipoproteinemia Type II/diagnosis ; Hyperlipoproteinemia Type II/genetics ; Male ; Middle Aged ; PCSK9 Inhibitors ; Phenotype ; Serine Proteinase Inhibitors/adverse effects

المؤلفون: Robinson JG; University of Iowa, Iowa City, IA, USA. Electronic address: jennifer-g-robinson@uiowa.edu., Farnier M; Lipid Clinic, Point Médical and Department of Cardiology, CHU Dijon-Bourgogne, Dijon, France., Kastelein JJP; Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands., Roth EM; The Sterling Research Group, Cincinnati, OH, USA., Taskinen MR; Research Program Unit, Clinical and Molecular Metabolism, University of Helsinki, Finland., Colhoun HM; University of Edinburgh, Edinburgh, UK., Brunet A; Sanofi, Clinical Development, R&D, Montpellier, France., DiCioccio AT; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Lecorps G; Sanofi, Chilly-Mazarin, France., Pordy R; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Baccara-Dinet MT; Sanofi, Clinical Development, R&D, Montpellier, France., Cannon CP; Harvard Clinical Research Institute, Boston, MA, USA.

المصدر: Journal of clinical lipidology [J Clin Lipidol] 2019 Nov - Dec; Vol. 13 (6), pp. 979-988.e10. Date of Electronic Publication: 2019 Oct 14.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 101300157 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1933-2874 (Print) Linking ISSN: 18764789 NLM ISO Abbreviation: J Clin Lipidol Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal, Humanized/*therapeutic use , Cholesterol, LDL/*blood , Proprotein Convertase 9/*blood, Antibodies, Monoclonal, Humanized/administration & dosage ; Anticholesteremic Agents/administration & dosage ; Anticholesteremic Agents/therapeutic use ; Double-Blind Method ; Female ; Humans ; Hypercholesterolemia/blood ; Hypercholesterolemia/drug therapy ; Hypercholesterolemia/metabolism ; Male ; Middle Aged ; Treatment Outcome

المؤلفون: Raal FJ; Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa. Electronic address: Frederick.raal@wits.ac.za., Tuomilehto J; Department of Public Health Solutions, National Institute for Health and Welfare, Helsinki, Finland; Diabetes Research Group, King Abdulaziz University, Jeddah, Saudi Arabia., Sposito AC; Cardiology Division, State University of Campinas School of Medicine (FCM Unicamp), Campinas, Brazil., Fonseca FA; Cardiology Division, Department of Medicine, Federal University of Sao Paulo, Sao Paulo, Brazil., Averna M; Department of Health Promotion Sciences Maternal and Infantile Care, Internal Medicine and Medical Specialties (PROMISE), School of Medicine, University of Palermo, Palermo, Italy., Farnier M; Department of Cardiology, Lipid Clinic, Point Médical, CHU Dijon Bourgogne, Dijon, France., Santos RD; Lipid Clinic Heart Institute (InCor), University of Sao Paulo Medical School Hospital, Hospital Israelita Albert Einstein, Sao Paulo, Brazil., Ferdinand KC; Department of Medicine, Heart and Vascular Institute, Tulane University School of Medicine, New Orleans, LA, USA., Wright RS; Department of Cardiology, Mayo Clinic, Rochester, MN, USA., Navarese EP; Interventional Cardiology and Cardiovascular Medicine Research, Mater Dei Hospital, Bari, Italy; Cardiovascular Institute, Ludwik Rydygier Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland; SIRIO MEDICINE Network, VA, USA., Lerch DM; Sanofi, Bridgewater, NJ, USA., Louie MJ; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Lee LV; Sanofi, Bridgewater, NJ, USA., Letierce A; Sanofi, Biostatistics and Programming, Chilly-Mazarin, France., Robinson JG; University of Iowa, Iowa City, IA, USA.

المصدر: Journal of clinical lipidology [J Clin Lipidol] 2019 Sep - Oct; Vol. 13 (5), pp. 735-743. Date of Electronic Publication: 2019 Jun 29.

نوع المنشور: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 101300157 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1933-2874 (Print) Linking ISSN: 18764789 NLM ISO Abbreviation: J Clin Lipidol Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal, Humanized/*therapeutic use , Hypertension/*drug therapy , Smoking/*adverse effects, Age Factors ; Aged ; Antibodies, Monoclonal, Humanized/adverse effects ; Cholesterol, LDL/blood ; Humans ; Hypertension/blood ; Middle Aged ; Risk Factors ; Treatment Outcome

المؤلفون: Dufour R; Institut de Recherches Cliniques de Montréal and Université de Montréal, Montréal, Quebec, Canada., Hovingh GK; Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands., Guyton JR; Duke University Medical Center, Durham, NC, USA., Langslet G; Lipid Clinic, Oslo University Hospital, Oslo, Norway., Baccara-Dinet MT; Clinical Development, R&D, Sanofi, Montpellier, France., Din-Bell C; Biostatistics and Programming, Sanofi, Chilly-Mazarin, France., Manvelian G; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Farnier M; Lipid Clinic, Point Médical and Department of Cardiology, CHU Dijon-Bourgogne, Dijon, France. Electronic address: michelfarnier@nerim.net.

المصدر: Journal of clinical lipidology [J Clin Lipidol] 2019 Jan - Feb; Vol. 13 (1), pp. 138-147. Date of Electronic Publication: 2018 Nov 30.

نوع المنشور: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 101300157 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1933-2874 (Print) Linking ISSN: 18764789 NLM ISO Abbreviation: J Clin Lipidol Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal, Humanized/*therapeutic use , Anticholesteremic Agents/*therapeutic use , Cholesterol, LDL/*blood , Hyperlipoproteinemia Type II/*drug therapy, Aged ; Drug Dosage Calculations ; Female ; Follow-Up Studies ; Humans ; Hyperlipoproteinemia Type II/genetics ; Male ; Middle Aged ; Precision Medicine ; Protein Serine-Threonine Kinases/antagonists & inhibitors ; Time Factors ; Treatment Outcome

المؤلفون: Kastelein JJ; aDepartment of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands bThe Christ Hospital, Heart and Vascular Center/The Lindner Research Center, Cincinnati, Ohio cHarvard Clinical Research Institute, Boston, Massachusetts dLouisville Metabolic and Atherosclerosis Research Center (L-MARC), Louisville, Kentucky eSanofi, Bridgewater, New Jersey fRegeneron Pharmaceuticals Inc., Tarrytown, New York, USA gBiostatistics and Programming, Sanofi, Chilly-Mazarin hPoint Médical, Dijon, France., Kereiakes DJ, Cannon CP, Bays HE, Minini P, Lee LV, Maroni J, Farnier M

المصدر: Coronary artery disease [Coron Artery Dis] 2017 May; Vol. 28 (3), pp. 190-197.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial

بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 9011445 Publication Model: Print Cited Medium: Internet ISSN: 1473-5830 (Electronic) Linking ISSN: 09546928 NLM ISO Abbreviation: Coron Artery Dis Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal, Humanized*/therapeutic use , Cholesterol, LDL*/drug effects , Dyslipidemias*/drug therapy , Hypolipidemic Agents*/therapeutic use, Dose-Response Relationship, Drug ; Double-Blind Method ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use

المؤلفون: Jennifer G. Robinson, Frederick J. Raal, Maurizio Averna, Keith C. Ferdinand, Michel Farnier, R. Scott Wright, L. Veronica Lee, Andrei C. Sposito, Danielle M. Lerch, Raul D. Santos, Michael J. Louie, Alexia Letierce, Jaakko Tuomilehto, Francisco Antonio Helfenstein Fonseca, Eliano Pio Navarese

المساهمون: Raal F.J., Tuomilehto J., Sposito A.C., Fonseca F.A., Averna M., Farnier M., Santos R.D., Ferdinand K.C., Wright R.S., Navarese E.P., Lerch D.M., Louie M.J., Lee L.V., Letierce A., Robinson J.G.

المصدر: Journal of Clinical Lipidology. 13:735-743

مصطلحات موضوعية: medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Hypercholesterolemia, Familial hypercholesterolemia, 030204 cardiovascular system & hematology, Antibodies, Monoclonal, Humanized, Placebo, law.invention, PCSK9, 03 medical and health sciences, Age, 0302 clinical medicine, Randomized controlled trial, Ezetimibe, Risk Factors, law, Internal medicine, Internal Medicine, medicine, Humans, 030212 general & internal medicine, Adverse effect, Aged, Alirocumab, Nutrition and Dietetics, business.industry, Smoking, Age Factors, Cholesterol, LDL, Middle Aged, medicine.disease, Cholesterol, Treatment Outcome, Concomitant, Hypertension, Cardiology and Cardiovascular Medicine, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffc8f347d591a93e0daa74152cad6402
https://doi.org/10.1016/j.jacl.2019.06.006

المؤلفون: Corinne Hanotin, Peter B. Jones, Elisabeth Steinhagen-Thiessen, Maurizio Averna, Helen M. Colhoun, Yunling Du, Stephen Donahue, Randall Severance, Michel Farnier

المساهمون: Farnier, M., Jones, P., Severance, R., Averna, M., Steinhagen-Thiessen, E., Colhoun, H., Du, Y., Hanotin, C., Donahue, S.

المصدر: Farnier, M, Jones, P, Severance, R, Averna, M, Steinhagen-Thiessen, E, Colhoun, H M, Du, Y, Hanotin, C & Donahue, S 2016, ' Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients : The ODYSSEY OPTIONS II randomized trial ', Atherosclerosis, vol. 244, pp. 138-46 . https://doi.org/10.1016/j.atherosclerosis.2015.11.010

مصطلحات موضوعية: Monoclonal antibody, medicine.medical_specialty, Time Factors, Settore MED/09 - Medicina Interna, Injections, Subcutaneous, Hypercholesterolemia, Urology, 030204 cardiovascular system & hematology, Pharmacology, Antibodies, Monoclonal, Humanized, law.invention, PCSK9, Rosuvastatin, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, Ezetimibe, Randomized controlled trial, law, medicine, Clinical endpoint, Humans, Low-density lipoprotein cholesterol, In patient, 030212 general & internal medicine, Rosuvastatin Calcium, Alirocumab, Cardiology and Cardiovascular Medicine, Retrospective Studies, Dose-Response Relationship, Drug, business.industry, Anticholesteremic Agents, Antibodies, Monoclonal, nutritional and metabolic diseases, Cholesterol, LDL, Treatment Outcome, Cardiovascular Diseases, Drug Therapy, Combination, Hydroxymethylglutaryl-CoA Reductase Inhibitors, business, Follow-Up Studies, medicine.drug

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfd7c2a81cb71fd157878238361dc5e5